Compare TRDA & LOVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TRDA | LOVE |
|---|---|---|
| Founded | 2016 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 274.5M | 227.3M |
| IPO Year | 2021 | 2018 |
| Metric | TRDA | LOVE |
|---|---|---|
| Price | $6.97 | $13.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $21.00 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 252.6K | 181.4K |
| Earning Date | 05-08-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | $25,421,000.00 | ★ $697,115,000.00 |
| Revenue This Year | $39.97 | $4.63 |
| Revenue Next Year | $50.80 | $6.40 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.42 |
| 52 Week Low | $4.93 | $10.33 |
| 52 Week High | $16.45 | $20.88 |
| Indicator | TRDA | LOVE |
|---|---|---|
| Relative Strength Index (RSI) | 45.70 | 35.48 |
| Support Level | $5.75 | $11.00 |
| Resistance Level | $7.02 | $15.59 |
| Average True Range (ATR) | 0.47 | 0.94 |
| MACD | 0.27 | -0.26 |
| Stochastic Oscillator | 72.36 | 7.76 |
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
The Lovesac Co designs, manufactures and sells alternative furniture which is comprised of modular couches called sactionals and premium foam beanbag chairs called sacs. It also offers other accessories such as sactional-specific drink holders, Footsac blankets, decorative pillows, fitted seat tables, and ottomans. Its products are sold across the United States through its website or company-owned retail stores which are used in homes and offices. The majority of the firm's revenue is derived from the sale of Sactionals.